Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03667170

KN035 for dMMR/MSI-H Advanced Solid Tumors

Study of KN035 as Monotherapy in Patients With Advanced Mismatched Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors

Sponsor: 3D Medicines (Sichuan) Co., Ltd.

Conditions Solid Tumor

Interventions KN035

Updated 10 times since 2018 Last updated: May 27, 2025 Started: Aug 22, 2018 Primary completion: Dec 30, 2025 Completion: Dec 15, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Solid Tumor and is currently actively recruiting participants. 3D Medicines (Sichuan) Co., Ltd. leads this study, which shows 10 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE2
May 2023 — Feb 2024 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

May 2022 — May 2023 [monthly]

Recruiting PHASE2
Apr 2022 — May 2022 [monthly]

Recruiting PHASE2
Apr 2021 — Apr 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Oct 2018 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

3D Medicines (Sichuan) Co., Ltd.

Data source: 3D Medicines

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China